Gastrointestinal Diseases: Clinical Trials

1,111 trials for Gastrointestinal Diseases, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

589 completed, 205 unknown, 101 terminated, 86 recruiting. 1111 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 41111Completed 589, Unknown 205, Terminated 101, Recruiting 86, Not yet recruiting 56, Withdrawn 51, Active not recruiting 18, Enrolling by invitation 4, Suspended 1

Follow Gastrointestinal Diseases: new trials by email Literature Review of Gastrointestinal Diseases trials Research Report on Gastrointestinal Diseases

Trials (filtered) newest first · largest first

All 1,111 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Dose Ranging Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Budesonide Rectal Foam in Pediatric Patients Aged 5 to 17 Years With Active, Mild to Moderate Distal Ulcerative Colitis
High dose budesonide rectal foam, Low dose budesonide rectal foam, Matching placebo rectal foam - Ulcerative Colitis
Phase 4Not yet recruitingBausch Health Americas, Inc.1002029-06-012026-10-06
ASAPP Study - Topical 5-ASA as Prophylaxis for Pouchitis in Ulcerative Colitis Patients After Pelvic Pouch Surgery
5-ASA, Placebo - Ulcerative Colitis (UC), Pouchitis
Phase 4Not yet recruitingUniversity Hospital, Linkoeping1102027-04-012026-08-19
Povidone-iodine Irrigation for Prevention of Intra-abdominal Abscess in Pediatric Perforated Appendicitis: a Multi-center Stepped Wedge Cluster Randomized Study
Irrigation with PVI, Usual care - Acute, Perforated Appendicitis
Phase 4Not yet recruitingThe University of Texas Health Science Center, Houston17502027-03-012025-02-10
Safety and Efficacy of a STOPping Strategy Versus Classical Maintenance Dose of JAK Inhibitors in Deep Remission Patients With Ulcerative Colitis
treatment withdrawal - Ulcerative Colitis in Remission
Phase 4Not yet recruitingAssistance Publique Hopitaux De Marseille2242027-01-012026-11-10
MIRICURE: Mirikizumab With Curettage and Repair (Closure) for Perianal Fistulizing Crohn's Disease
Mirikizumab, Fistula Tract Curettage and Closure - Crohn's Disease, Perianal Fistula
Phase 4Not yet recruitingIcahn School of Medicine at Mount Sinai502026-12-012026-08-24
FirST Lines of Biologics in pAtients With ulceRaTivE Colitis: a Randomised Controlled Trial
1: infliximab 2: filgotinib 3: ustekinumab 4: vedolizumab, 1: ustekinumab 2: vedolizumab 3: infliximab 4: filgotinib, 1: vedolizumab 2: infliximab 3: filgotinib 4: ustekinumab - Ulcerative Colitis (UC)
Phase 4Not yet recruitingUniversity Hospital, Clermont-Ferrand2402026-12-012026-10-21
A Study of Zolbetuximab Given With mFOLFOX6 or CAPOX Chemotherapy in Indian Adults With Gastric Cancer
Zolbetuximab, Oxaliplatin, Folinic Acid - Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer
Phase 4Not yet recruitingAstellas Pharma Global Development, Inc.502026-11-302026-09-21
Efficacy of Upadacitinib Re-induction Therapy in Patients With Ulcerative Colitis Who Lost Response to 30 mg Maintenance Dose
Upadacitinib - Ulcerative Colitis (UC)
Phase 4Not yet recruitingGroupe d'Etude Therapeutique des Affections Inflammatoires Digestives1002026-11-152026-10-29
Tucatinib Continuation Study
tucatinib - HER2-positive Breast Cancer, Cervical Cancer
Phase 4Not yet recruitingPfizer1752026-11-062026-08-28
A Trial of Pembrolizumab With Chemotherapy or Chemoradiotherapy in Participants From India With Different Types of Cancer (MK-3475-G44/KEYNOTE-G44)
Pembrolizumab, Cisplatin, 5-Fluorouracil - Neoplasm Malignant, Gastric Neoplasms
Phase 4Not yet recruitingMerck Sharp & Dohme LLC1502026-11-062026-09-03
Emerging Indications for Hyperbaric Oxygen Treatment
Hyperbaric oxygen treatment (HBOT), 100% Oxygen - Post-COVID-19 Condition, Ulcerative Colitis
Phase 4Not yet recruitingJay C. Buckey Jr.1002026-11-012026-09-09
Vonoprazan High-Dose Dual VS Levofloxacin Concomitant
Vonoprazan, Levofloxacin 500mg - Helicobacter Pylori Infection, Peptic Ulcer Disease
Phase 4Not yet recruitingDamascus Hospital1502026-11-012026-06-03
Efficacy of Potassium-Competitive Acid Blockers in Barrett's Esophagus (PCAB BE Study)
Potassium-Competitive Acid Blockers (PCABs) - Barrett Esophagus
Phase 4RecruitingUniversity of North Carolina, Chapel Hill122026-11-012026-11-05
PPI Dosing Per CYP2C19 Genotype
CYP2C19 based dosing Proton Pump Inhibitors, Conventional proton pump inhibitor dose - Gastroesophageal Reflux Disease With Esophagitis
Phase 4RecruitingUniversity of Florida2002026-11-012026-11-12
Effects of Tirzepatide on Esophagogastric Junction Mechanics, Reflux Burden, and Gastric Physiology in Adults With Obesity
Placebo, Tirzepatide - Obese Adults
Phase 4Not yet recruitingMayo Clinic302026-10-262026-10-26
Upadacitinib in Patients Hospitalized With Acute Severe Ulcerative Colitis
Upadacitinib - UC - Ulcerative Colitis
Phase 4Not yet recruitingUniversity of California, San Francisco502026-10-152026-09-24
Antibiotics After Incision and Drainage to Prevent Fistula Formation After First Episode of Perianal Abscess
Amoxicillin + Clavulanate, Ciprofloxacin + Metronidazole - Perianal Abscess, Anal Fistula
Phase 4Not yet recruitingUniversity of Illinois at Chicago2362026-10-052026-09-21
Risankizumab for Refractory Perianal Fistulizing Crohn's Disease
Risankizumab - Crohn Disease, Perianal Fistula
Phase 4RecruitingYuki Horio252026-10-012026-10-23
Combination CurQD and Vedolizumab in Ulcerative Colitis
CurQD, Placebo, Vedolizumab - Ulcerative Colitis
Phase 4Not yet recruitingRyan C Ungaro1602026-10-012026-10-05
Assessing the Feasibility of Using Methylene Blue in Identifying Ureters During Colorectal Surgery
Intravenous Methylene Blue, Methylene Blue Fluorescence Imaging System - Colorectal Cancer, Colorectal Surgery
Phase 4Not yet recruitingChinese University of Hong Kong202026-10-012026-10-06

Showing 20 of 1111. Sign in to see all of them.

Narrower conditions

Crohn Disease (151)  ·  Colitis, Ulcerative (127)  ·  Gastroesophageal Reflux (116)  ·  Colorectal Neoplasms (106)  ·  Inflammatory Bowel Diseases (80)  ·  Stomach Neoplasms (66)  ·  Irritable Bowel Syndrome (58)  ·  Gastrointestinal Hemorrhage (41)  ·  Colonic Neoplasms (38)  ·  Peptic Ulcer (36)  ·  Appendicitis (31)  ·  Esophageal Neoplasms (28)  ·  Esophageal and Gastric Varices (23)  ·  Rectal Neoplasms (22)  ·  Diarrhea (21)

Broader conditions

Digestive System Diseases (1104)  ·  Intestinal Diseases (709)  ·  Gastroenteritis (392)  ·  Colonic Diseases (333)  ·  Pathological Conditions, Signs and Symptoms (309)  ·  Neoplasms (266)  ·  Neoplasms by Site (255)  ·  Digestive System Neoplasms (254)  ·  Gastrointestinal Neoplasms (242)  ·  Esophageal Diseases (229)  ·  Inflammatory Bowel Diseases (189)  ·  Pathologic Processes (179)  ·  Rectal Diseases (165)  ·  Intestinal Neoplasms (157)

Interventions

Esomeprazole (63)  ·  Infliximab (42)  ·  Omeprazole (36)  ·  vedolizumab (32)  ·  Lansoprazole (28)  ·  Rabeprazole (23)  ·  Adalimumab (22)  ·  Metronidazole (22)  ·  Amoxicillin (21)  ·  Pantoprazole (21)  ·  Capecitabine (17)  ·  Mesalamine (17)  ·  Oxaliplatin (17)  ·  Fluorouracil (16)  ·  Sodium Chloride (15)

Sponsors

AstraZeneca (27)  ·  Takeda (22)  ·  Universitaire Ziekenhuizen KU Leuven (16)  ·  Mayo Clinic (15)  ·  Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives (14)  ·  Xijing Hospital of Digestive Diseases (13)  ·  Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) (8)  ·  Chinese University of Hong Kong (8)  ·  Hoffmann-La Roche (8)  ·  Fudan University (7)  ·  Kaohsiung Veterans General Hospital. (7)  ·  Medical University of Warsaw (7)  ·  University of North Carolina, Chapel Hill (7)  ·  Yonsei University (7)  ·  Asan Medical Center (6)

Countries

United States (275)  ·  China (125)  ·  France (59)  ·  South Korea (57)  ·  Canada (54)  ·  Italy (54)  ·  Netherlands (43)  ·  Spain (43)  ·  Denmark (42)  ·  Taiwan (42)  ·  United Kingdom (38)  ·  Belgium (37)  ·  Germany (32)  ·  Israel (27)  ·  Poland (24)

Top investigators

Paula Fernstrom (8)  ·  Arie Levine, MD (5)  ·  Yongquan Shi, Ph. D (4)  ·  Bor-Shyang Sheu, MD (3)  ·  Brian G Feagan, MD (3)  ·  Dan Turner, MD, PhD (3)  ·  Jinming Yu, Ph.D, M.D (3)

Results publications

PMID 25018650, PMID 40013523, PMID 40357993, PMID 11668104, PMID 23152962, PMID 25478944, PMID 37526194, PMID 10022643, PMID 10049409, PMID 10343249, PMID 10395629, PMID 10403850, PMID 10536559, PMID 10626860, PMID 10896917, PMID 10950834, PMID 11052511, PMID 11156645, PMID 11256129, PMID 11822956, PMID 11857360, PMID 12041718, PMID 12127688, PMID 12161727, PMID 12170403, PMID 12194122, PMID 12219064, PMID 12432298, PMID 12492746, PMID 1305308, PMID 14570648, PMID 14644354, PMID 14762782, PMID 1479177, PMID 1499440, PMID 15044883, PMID 15058524, PMID 15094271, PMID 15168373, PMID 15479678, PMID 15488052, PMID 15519198, PMID 15555725, PMID 15572881, PMID 15645403, PMID 15738894, PMID 15793647, PMID 15818423, PMID 15838899, PMID 15843939

NIH funding

2014 (12), 2025 (8), 2015 (6), 2009 (5), 2017 (5), 2016 (4), 2019 (4), 2008 (3), 2018 (2), 2023 (2), 2005 (1), K12TR004908 (1), K23DK115827 (1), K23DK124567 (1), K23DK131317 (1)